Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor-selective agonists. Efficacy and safety were assessed in mice with diet-induced obesity (DIO) and those with leptin-deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU-6102) and NMU2 (NMU-2084), along with non-selective NMU1/2 agonists (NMU-0002 and NMU-6014). We also performed immunohistochemistry for c-Fos protein expression in the brain to probe their mechanisms of action. Although both non-selective NMU1/2 agonists and the NMU2-selective agonist had high efficacy compared with the NMU1-selective agonist, only the NMU2-selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non-selective NMU1/2 agonist and the NMU1-selective agonist, but not the NMU2-selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2-selective agonists preferentially activate pro-opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus. These results suggest that an NMU2 receptor-selective agonist may be a well-balanced drug for the treatment of obesity and that an NMU1 receptor-selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized. © 2017 The British Pharmacological Society.

Citation

Hiroaki Nagai, Tomoko Kaisho, Kotaro Yokoyama, Tomoko Asakawa, Hisashi Fujita, Kouta Matsumiya, Jiro Noguchi, Kazue Tsuchimori, Naoki Nishizawa, Yoko Kanematsu-Yamaki, Katsuko Dote, Hiroshi Inooka, Jun-Ichi Sakamoto, Tetsuya Ohtaki, Taiji Asami, Shiro Takekawa. Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice. British journal of pharmacology. 2018 Jan;175(2):359-373

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 29057457

View Full Text